Salta al contenuto principale
Passa alla visualizzazione normale.

MARIANGELA LIBRIZZI

Pubblicazioni

Data Titolo Tipologia Scheda
2018 Mid-region parathyroid hormone-related protein is a genome-wide chromatin-binding factor that promotes growth and differentiation of HB2 epithelial cells from the human breast Articolo in rivista Vai
2017 Jay Amin Hydroxamic Acid (JAHA), a histone deacetylase inhibitor with cytotoxic activity and the property to increase DNA repair of triple-negative MDA-MB231 breast cancer cells. Proceedings (TIPOLOGIA NON ATTIVA) Vai
2017 Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA Articolo in rivista Vai
2016 Biological effect of a hybrid anticancer agent based on kinase and histone deacetylase inhibitors on triple-negative (MDA-MB231) breast cancer cells Articolo in rivista Vai
2015 The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells Articolo in rivista Vai
2015 Effect of conditioned media from osteo- and adipo-differentiating mesenchymal stem cells on triple negative MDA-MB231 breast cancer cells Abstract in rivista Vai
2015 Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells Articolo in rivista Vai
2015 The conditioned medium from osteo-differentiating human mesenchymal stem cells affects the viability of triple negative MDA-MB231 breast cancer cells Articolo in rivista Vai
2014 Biological effect of an hybrid anticancer agent based on kinase and histone deacetylase inhibitor on breast cancer cells Proceedings (TIPOLOGIA NON ATTIVA) Vai
2014 The effect of the HDACi JAHA on DNA methylation of breast cancer cells by down-regulating DNMT1 through ERK signaling Proceedings (TIPOLOGIA NON ATTIVA) Vai
2014 Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors Articolo in rivista Vai
2014 Gene and protein signatures associated to treatment of MDA-MB231 breast cancer cells with JAHA, a novel histone deacetylase inhibitor Proceedings (TIPOLOGIA NON ATTIVA) Vai
2013 PTHrP in differentiating human mesenchymal stem cells: transcript isoform expression, promoter methylation, and protein accumulation Articolo in rivista Vai
2013 JAHA, a novel histone deacetylase inhibitor: cytotoxic effect on triple-negative breast cancer cells Proceedings (TIPOLOGIA NON ATTIVA) Vai
2013 Effect of conditioned media from osteo- and adipodifferentiating mesenchymal stem cells on triple negative MDA-MB231 breast cancer cells Proceedings (TIPOLOGIA NON ATTIVA) Vai
2013 Effect of transfection with PLP2 antisense oligonucleotides on gene expression of cadmium-treated MDA-MB231 breast cancer cells Articolo in rivista Vai
2013 Effetto citotossico di un nuovo inibitore delle deacetilasi istoniche, JAHA, su cellule di tumore mammario umano triplo negativo Proceedings (TIPOLOGIA NON ATTIVA) Vai
2012 Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells Articolo in rivista Vai
2012 JA47, a new histone deacetylase inhibitor that induces cytotoxic effects on triple-negative MDA-MB231 breast cancer cells in vitro Proceedings (TIPOLOGIA NON ATTIVA) Vai
2012 Cytotoxic effects induced by JA47, a novel histone deacetylase inhibitor (HDACi), on MDA-MB231 breast cancer cells Proceedings (TIPOLOGIA NON ATTIVA) Vai